Why Are You Choosing a Certain Testing Platform in Biomarker Testing?

April 29, 2024

News

Video

Related Videos

Benjamin Garmezy, MD

Jeffrey P. Townsend, PhD

Michael Iglesia, MD, PhD

Jean L. Koff, MD, MS

Rohan Garje, MD

Nan Chen, MD

Sundar Jagannath, MBBS

Related Content

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health

Georgetown’s Cancer Center Awarded Top Designation by National Cancer Institute; Comprehensive Cancer Center Consortium Includes Hackensack Meridian’s John Theurer Cancer Center

Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

Petros Grivas, MD, PhD, of Seattle Cancer Care Alliance

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

R. Lor Randall, MD, FACS, David Linn Endowed Chair for Orthopedic Surgery, chair, Department of Orthopedic Surgery, professor, University of California Davis Comprehensive Cancer Center

Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma

Related Content

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health

Georgetown’s Cancer Center Awarded Top Designation by National Cancer Institute; Comprehensive Cancer Center Consortium Includes Hackensack Meridian’s John Theurer Cancer Center

Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

Petros Grivas, MD, PhD, of Seattle Cancer Care Alliance

Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer

R. Lor Randall, MD, FACS, David Linn Endowed Chair for Orthopedic Surgery, chair, Department of Orthopedic Surgery, professor, University of California Davis Comprehensive Cancer Center

Guideline-Concordant Care Is Associated With Reduced Risk of Death in Metastatic Osteosarcoma

Latest Conference Coverage

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.